Has Adam Carpenter, MD received payments from drug or device companies?

Yes. Drug and device makers reported $129 in general payments to Adam Carpenter, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adam Carpenter, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adam Carpenter, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adam Carpenter, MD

Neurology · Minneapolis, MNNPI 1942355490

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Abiomed at 50.2% of the total. 2024 is the largest year on record at $98, 6.7 times the $15 reported in 2019. That places this record below the midpoint for neurology clinicians in MN, where the typical reported total is $117.

$129in general payments, 2019–2025

Across 5 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abiomed$65
Sumitomo Pharma America, Inc.$33
Biogen$16
Novo Nordisk$15

$413,968in research payments, 2019–2025

Across 100 payments — averaging $4139.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mallinckrodt Hospital Products Inc.$192K
F. Hoffmann-la Roche AG$73K
Roche Products Limited$53K
Biogen$43K
Hoffmann-la Roche Limited$30K
Mallinckrodt Enterprises LLC$18K
plus $6K from 2 others

What the payments were for

Food & beverage$129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abiomed	2	$65
Sumitomo Pharma America, Inc.	1	$33
Biogen	1	$16
Novo Nordisk	1	$15

How this compares

$129 in reported general payments places this provider in the 50th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$10,773

Medicare patients

Services billed

132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RebifInterferon Beta-1a/Albumin	13	$161,137
AubagioTeriflunomide	12	$112,339
TecfideraDimethyl Fumarate	11	$102,230
AmpyraDalfampridine	16	$68,779
Glatiramer Acetate	25	$40,343
Dalfampridine ErDalfampridine	120	$22,197
QuliptaAtogepant	11	$12,037
Tolterodine Tartrate ErTolterodine Tartrate	13	$3,862
Baclofen	152	$3,135
Gabapentin	105	$2,249
Dimethyl Fumarate	11	$1,862
Solifenacin Succinate	23	$1,549
Methenamine Hippurate	17	$1,311
Modafinil	27	$1,122
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine	14	$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
BiogenTecfidera	$16	$102,23011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 434 neurology providers in Minnesota.

Other neurology in Minneapolis

Jeffery AllenMinneapolis$1.1M
Jerrold VitekMinneapolis$97K
Leonardo Brito de AlmeidaMinneapolis$80K
Kamaskshi LakshminarayanMinneapolis$64K
Sanjay SinghMinneapolis$42K
Elizabeth NeilMinneapolis$26K
Allyson ConnorMinneapolis$23K
Kelsey JensenMinneapolis$22K
Javier Suarez OliverosMinneapolis$22K
Ilo LeppikMinneapolis$18K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →